Apellis Pharmaceuticals to Present at the Bank of America Securities 2022 Healthcare Conference
Apellis Pharmaceuticals (Nasdaq: APLS) announced its participation at the Bank of America Securities 2022 Healthcare Conference on May 11, 2022, at 8:40 a.m. PT.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Apellis Pharmaceuticals (Nasdaq: APLS) announced its participation at the Bank of America Securities 2022 Healthcare Conference on May 11, 2022, at 8:40 a.m. PT. The event will feature a live webcast accessible through the company’s website, and a replay will be available for 30 days afterward.
As a leader in complement therapies, Apellis focuses on developing transformative treatments for diseases related to complement cascade activation across various fields, including hematology, ophthalmology, nephrology, and neurology.
Details
News Market Reaction – APLS
The recorded move for APLS in the trading session of this news was -8.75%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
WALTHAM, Mass., May 05, 2022 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced that the company will present at the Bank of America Securities 2022 Healthcare Conference on Wednesday, May 11, 2022 at 8:40 a.m. PT .
The event will be available via a live webcast from the “Events and Presentations” page of the “Investors and Media” section of the company’s website. A replay of the webcast will be available for 30 days following the event.
About Apellis
Apellis Pharmaceuticals, Inc. is a global biopharmaceutical company that is committed to leveraging courageous science, creativity, and compassion to deliver life-changing therapies. Leaders in targeted C3 therapies, we aim to develop transformative therapies for a broad range of debilitating diseases that are driven by excessive activation of the complement cascade, including those within hematology, ophthalmology, nephrology, and neurology. For more information, please visit www.apellis.com.
Investor Contact:
Meredith Kaya
meredith.kaya@apellis.com
617.599.8178
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.